Waszkiewicz Napoleon, Szajda Sławomir Dariusz, Konarzewska-Duchnowska Emilia, Zalewska-Szajda Beata, Gałązkowski Robert, Sawko Anna, Nammous Halim, Buko Vyacheslav, Szulc Agata, Zwierz Krzysztof, Ładny Jerzy Robert
Department of Psychiatry, Medical University of Bialystok, Poland.
Department of Emergency Medicine and Disasters, Medical University of Bialystok, Poland.
Postepy Hig Med Dosw (Online). 2015 Apr 8;69:436-9. doi: 10.5604/17322693.1148704.
Colorectal cancer is characterized by high morbidity and mortality in developed countries. The lack of low-cost, easy-to-use screening diagnostic methods is one of the causes of late diagnosis of colorectal cancer. Beta-glucuronidase (GLU) is a lysosomal exoglycosidase involved in degradation of glycosaminoglycans of the cell membranes and extracellular matrix of normal and cancerous colon tissues. The aim of our research was to evaluate the activity of GLU in the serum of colorectal cancer and estimate its potential value in the diagnosis of colorectal cancer.
Blood samples were collected from 21 patients with colorectal adenocarcinoma and 17 healthy subjects. GLU activity was determined by the colorimetric method of Marciniak et al. by measuring the amount of p-nitrophenol released from 4-nitrophenyl-beta-D-glucuronide, at λ = 405 nm.
We found significantly greater activity of GLU (p<0.0001) in the serum of patients with colorectal cancer, as compared to the healthy subjects. The serum GLU activity significantly differentiates patients with colorectal cancer from healthy individuals.
Serum GLU activity has diagnostic value and may be used in the diagnosis of colon adenocarcinoma.
